For the quarter ending 2025-09-30, PRLD made $6,500,000 in revenue. -$19,722,000 in net income. Net profit margin of -303.42%.
| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
| Revenue | 6,500,000 | - | - | 1,333,333.333 |
| Research and development | 21,708,000 | 25,784,000 | 28,816,000 | 29,512,666.667 |
| General and administrative | 5,210,000 | 6,410,000 | 5,790,000 | 6,933,333.333 |
| Total operating expenses | 26,918,000 | 32,194,000 | 34,606,000 | 36,446,000 |
| Loss from operations | -20,418,000 | -32,194,000 | -34,606,000 | -35,112,666.667 |
| Other income, net | 693,000 | 963,000 | 2,521,000 | 3,478,666.667 |
| Net loss | -19,725,000 | -31,231,000 | -32,085,000 | -31,634,000 |
| Unrealized gain (loss) on marketable securities, net of tax | 3,000 | -13,000 | -23,000 | -215,000 |
| Comprehensive loss | -19,722,000 | -31,244,000 | -32,108,000 | -31,849,000 |
| Earnings per share, basic, total | -0.26 | -0.41 | -0.42 | -0.417 |
| Earnings per share, diluted, total | -0.26 | -0.41 | -0.42 | -0.417 |
| Weighted average number of shares outstanding, basic, total | 76,132,337 | 75,993,941 | 75,986,281 | -16,703 |
| Weighted average number of shares outstanding, diluted, total | 76,132,337 | 75,993,941 | 75,986,281 | -16,703 |
Prelude Therapeutics Inc (PRLD)
Prelude Therapeutics Inc (PRLD)